Heart Disease
Is Angiogenesis a Treatment or Cure for Severe Heart Disease?
Zhittya Genesis Medicine is developing a drug, fibroblast growth factor 1 (FGF-1), to treat Coronary Heart Disease (CAD) by growing new blood vessels around blockages in the heart. Thereby, increasing blood supply and extending the life expectancy of patients by years and even decades, while also reducing pain and increasing quality of life.
Over 80 patients with CAD have been dosed with FGF-1 in three different clinical trials in the United States and Germany over the last 20 years. All patients showed great improvement, with no adverse events reported attributable to FGF-1 in the studies. The successful results of these studies were posted in Circulation, the American Heart Association’s peer-reviewed journal.
Zhittya plans to restart its research into Coronary Artery Disease in both clinical trials and medical research studies for the public.
Zhittya has also seen great success outside the heart in their Medical Research Studies where, as of June 2024, Zhittya has dosed over 200 individuals with various diseases. Beyond demonstrating impressive safety data in all patients, it has also shown great improvement where it has improved prognosis and quality of life, and in some diseases even reversing its damage.
Our Data: Pictured and Graphed
Watch as Zhittya Genesis Medicine’s drug is used to grow new blood vessels in the human heart in a US FDA Phase I Clinical Trial done at the University of Cincinnati, and reported by ABC Nightly News.
In a US FDA Phase I Clinical Trial, FGF-1 was able to grow around blocked arteries in the heart. By growing around these blocked arteries, FGF-1 was able to treat coronary artery disease, allowing for these patients to reduce chest pain and begin to return to normal. The plush shown on the right side indicates new blood vessels growing around the blocked arteries in the heart.
History
The first coronary artery disease trial in humans with FGF-1 was performed in Germany at the Fulda Medical Center in Fulda, Germany. 40 patients were in the study, and 20 patients received FGF-1.
In all 20 patients that received FGF-1, a blush of new blood vessels could be observed on angiograms. Blood vessel density increased by three times and remained three years after the treatment, supplying blood and nutrients to the heart.
A second trial in Germany would follow, focusing on both safety and efficacy of the drug. The conclusion of the study indicated that not only was the drug safe, showing no adverse events; but that patients had improved in heart pain, heart stress, and exercise scoring.
After these successful trials, technology would be transferred to the United States to conduct a US FDA Phase I Clinical Trial in partnership with the University of Cincinnati. 21 patients would be recruited for this trial, resulting in statistical improvements after only 12 weeks. The results were so impressive that the American Broadcasting Channel (ABC) would go on to make a report about it.
Watch as Zhittya Genesis Medicine’s drug is used to grow new blood vessels in the human heart in a US FDA Phase I Clinical Trial done at the University of Cincinnati, and reported by ABC Nightly News.
Watch Zhittya's full presentation discussing how FGF-1 could be used to treat Coronary Artery Disease by growing blood vessels around blocked arteries in the heart. A process which has demonstrated to be effective in three clinical trials in Europe and the United States.
Our Partners
-
![]()
University of Nevada, Reno
Zhittya Genesis Medicine continue to cooperate and work with research and laboratory staff at the University of Nevada, Reno. Zhittya conducts some of its research related to FGF-1 and Coronary Artery Disease here.
-
![]()
Cross Border Medical Tourism
Zhittya Genesis Medicine’s partner in patient facilitation, patient logistics, and operations based in Los Angeles, California. Cross Border Medical Tourism ensures that all of our patients are cared for throughout our programs.
-
![]()
Wund Healing Biopharmaceuticals
Zhittya Genesis Medicine’s marketing partner based in Las Vegas, Nevada, helping Zhittya Genesis Medicine market and distribute our potential treatment(s) following anticipated approval by the US FDA and other regulatory bodies.
-
![]()
The Bahamas Heart Centre
Zhittya Genesis Medicine’s partner in research based in The Bahamas has world-class facilities for treating people with severe and no-option heart disease. The Bahamas Heart Centre, located in The Bahamas Medical Pavillion is one of the world’s leaders in research, holding multiple US and international accreditations for its quality facilities and groundbreaking research.
News
-
![]()
June 2024 Update
Zhittya Genesis Medicine’s June 2024 update highlights significant advancements in their research and treatment initiatives. The company has begun recruiting patients with severe, no-option heart disease for medical research studies in The Bahamas, marking a crucial step in their efforts to combat heart disease, the leading cause of death globally
-
![]()
Zhittya Research Study Approved in The Bahamas!
Zhittya Genesis Medicine has obtained regulatory clearance to begin conducting research studies in The Bahamas. Zhittya Genesis Medicine will begin utilizing FGF-1 in patients suffering from severe Coronary Artery Disease by injecting FGF-1 directly into the heart via a mini-thoracotomy. This less invasive method should allow for better patient outcomes and more patient comfort.
-
![]()
Zhittya Finishes Additional Production of FGF-1
Zhittya Genesis Medicine completes the production of additional FGF-1 with its partners. This new batch of FGF-1 will allow for Zhittya Genesis Medicine to continue to conduct studies into the future for Parkinson’s Disease.
